• Home
  • NEW DAY MEDICINE
  • 10 (72) 2024
  • 27 -10 (72) 2024 - Mun A.V., Kobiljonova D.Sh. - JANUS KINASE INHIBITORS IN DERMATOLOGY: EFFECTIVE STRATEGIES AND CLINICAL PROSPECTS

27 -10 (72) 2024 - Mun A.V., Kobiljonova D.Sh. - JANUS KINASE INHIBITORS IN DERMATOLOGY: EFFECTIVE STRATEGIES AND CLINICAL PROSPECTS

JANUS KINASE INHIBITORS IN DERMATOLOGY: EFFECTIVE STRATEGIES AND CLINICAL PROSPECTS

Kosimov Kh.O. - Tashkent Pediatric Medical Institute

Kobiljonova D.Sh. - Tashkent Pediatric Medical Institute

Nizamova D.F. - Tashkent Pediatric Medical Institute

Resume

The growing interest in Janus kinase (JAK) inhibitors is primarily due to their potential for the treatment of a variety of inflammatory and autoimmune diseases. Janus kinases (JAKs) have become promising therapeutic targets in dermatology due to their important role in various inflammatory skin diseases. By understanding their functions and interactions, researchers and clinicians are developing innovative strategies to treat diseases such as psoriasis, atopic dermatitis, and vitiligo.

Keywords: Janus Kinases, Atopic dermatitis, vitiligo, STAT proteins

First page

174

Last page

180

For citation:Mun A.V., Kobiljonova D.Sh., Nizamova D.F. - JANUS KINASE INHIBITORS IN DERMATOLOGY: EFFECTIVE STRATEGIES AND CLINICAL PROSPECTS//New Day in Medicine 10(72)2024 174-180 https://newdayworldmedicine.com/en/new_day_medicine/10-72-2024

List of References

  1. O’Shea J.J., Kontzias A., Yamaoka K., Tanaka Y., Laurence A. Janus kinase inhibitors in autoimmune diseases. //Ann Rheum Dis. 2013;72(suppl 2)(0 2):ii111- 115. PMID: 23532440; PMCID: PMC3616338. https://doi.org/10.1136/annrheumdis-2012-202576
  2. Aittomäki S., Pesu M. Therapeutic targeting of the Jak/STAT pathway. Basic Clin Pharmacol Toxicol. 2014;114(1):18-23. Epub 2013 Nov 15. PMID: 24164900. https://doi.org/10.1111/bcpt.12164
  3. Ghoreschi K., Laurence A., O’Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be? //Nat Immunol. 2009;10(4):356-60. Epub 2009 Mar 19. PMID: 19295632; PMCID: PMC2758543. https://doi.org/10.1038/ni.1701
  4. O’Shea J.J., Schwartz D.M., Villarino A.V., Gadina M., McInnes I.B., Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. //Annu Rev Med. 2015;66:311-328. PMID: 25587654; PMCID: PMC5634336. https://doi.org/10.1146/annurev-med-051113-024537 5.
  5. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. //Science. 1994;264(5164):1415-1421. PMID: 8197455. https://doi.org/10.1126/science.8197455
  6. K.A. Papp, A. Menter, B. Strober, R.G. Langley, M. Buonanno, R. Wolk, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study: tofacitinib improves the clinical signs of psoriasis. //Br J Dermatol, 2012;167:668-677.
  7. H. Bachelez, P.C.M. van de Kerkhof, R. Strohal, A. Kubanov, F. Valenzuela, J.-H. Lee, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. //Lancet Lond Engl, 2015;386:552-561.
  8. K.A. Papp, M.A. Menter, M. Abe, B. Elewski, S.R. Feldman, A.B. Gottlieb, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. //Br J Dermatol, 2015;173:949-961.
  9. K.A. Papp, J.G. Krueger, S.R. Feldman, R.G. Langley, D. Thaci, H. Torii, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. //J Am Acad Dermatol, 2016;74:841-850.
  10. J.F. Merola, B. Elewski, S. Tatulych, S. Lan, A. Tallman, M. Kaur. Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. //J Am Acad Dermatol, 77 (2017), pp. 79-87
  11. S.R. Feldman, D. Thaçi, M. Gooderham, M. Augustin, C. de la Cruz, L. Mallbris, et al. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. //J Am Acad Dermatol, 75 (2016), pp. 1162-1170
  12. A. Asahina, T. Etoh, A. Igarashi, S. Imafuku, H. Saeki, Y. Shibasaki, et al.Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. //J Dermatol, 43 (2016), pp. 869-880
  13. W.C. Ports, S. Khan, S. Lan, M. Lamba, C. Bolduc, R. Bissonnette, et al.A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. //Br J Dermatol, 169 (2013), pp. 137-145
  14. K.A. Papp, R. Bissonnette, M. Gooderham, S.R. Feldman, L. Iversen, J. Soung, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. //BMC Dermatol, 16 (2016), pp. 15
  15. K.A. Papp, M.A. Menter, M. Raman, D. Disch, D.E. Schlichting, C. Gaich, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. //Br J Dermatol, 174 (2016), pp. 1266-1276
  16. G.J. Schmieder, Z.D. Draelos, D.M. Pariser, C. Banfield, L. Cox, M. Hodge, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. //Br J Dermatol, 179 (2018), pp. 54-62
  17. V.J. Ludbrook, K.J. Hicks, K.E. Hanrott, J.S. Patel, M.H. Binks, M.R. Wyres, et al. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. //Br J Dermatol, 174 (2016), pp. 985-995
  18. R. Bissonnette, M. Luchi, R. Fidelus-Gort, S. Jackson, H. Zhang, R. Flores, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. //J Dermatol Treat, 27 (2016), pp. 332-338
  19. Oral JAK Inhibitor Smyraf® Tablets approved in Japan for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have an inadequate response to conventional therapies | Astellas Pharma Inc. GLOBAL WEBSITE [Internet]. Available from: https://www.astellas.com/en/news/14651
  20. http://refhub.elsevier.com/S1578-2190(21)00168-2/sbref0720

    file

    download